Rivaroxaban versus enoxaparin to prevent blood clots after exploratory laparotomy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized controlled trial at Mayo Hospital Lahore comparing once-daily oral rivaroxaban (10 mg) with once-daily subcutaneous enoxaparin (40 mg) for seven days after emergency exploratory laparotomy in adults aged 18–80. Participants are randomized with allocation concealment and receive standard perioperative care plus the assigned anticoagulant. Leg duplex Doppler ultrasounds are performed on postoperative day 5 and day 10 to detect deep vein thrombosis, and patients are monitored for bleeding and other adverse events. The trial excludes patients with preoperative DVT, morbid obesity (BMI ≥40), mechanical ventilation, recent myocardial infarction or stroke, or ongoing anticoagulation.

Why it matters

Who can join: the full rules

Inclusion Criteria:• Patients aged 18 to 80 years

* Both male or female patients
* Patients who have undergone emergent exploratory laparotomy for any reason whether traumatic or non-traumatic
* Patients with expected immobility for more than 24 hours

Exclusion Criteria:

* Patients with diagnosed pre-operative DVT
* BMI more than 40
* Patient who are on mechanical ventilation post operatively
* Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident
* Patients who have undergone limb surgery in addition to exploratory laparotomy

Where it's running

• Mayo Hospital Lahore
  Lahore, Punjab Province, Pakistan Recruiting

Study contacts

• Study coordinator: Muhammad Mashhood Shad, FCPS
• Email: mashhood_shad@yahoo.com
• Phone: +923040420285

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prehabilitation within ERAS for gynecologic oncology surgery

  This trial tests whether a pre-surgery program of tailored exercise, immunonutrition (Ocoxin), breathing exercises and psychological support combined with ERAS helps people having gynecologic cancer surgery recover faster and with fewer complications.

  Recruiting Aristotle University Of Thessaloniki · Thessaloniki · NCT07210164

• GORE VIABAHN FORTEGRA Venous Stent Post-Approval Study

  This study tests the GORE VIABAHN FORTEGRA Venous Stent in real-world patients with venous diseases to see how it performs after it is approved.

  Recruiting at 4 sites W.L.Gore & Associates · Darien, Connecticut and 3 other locations · NCT07538609

• Personalized blood thinner treatment for hip and knee replacement patients

  This study is testing if personalized blood thinner treatments can better prevent blood clots and bleeding in patients getting hip or knee replacements compared to standard treatments.

  Recruiting at 12 sites Phase 4 Leiden University Medical Center · Apeldoorn, Gelderland and 12 other locations · NCT06581965

• Investigating Clonal Hematopoiesis and Neutrophil Extracellular Traps in Venous Thrombosis

  This study is trying to see if certain blood changes are linked to repeated blood clots in younger people who don’t have the usual risk factors.

  Recruiting at 3 sites University Hospital, Bordeaux · Bordeaux and 6 other locations · NCT05711173

• Cancer-associated VTE: A follow-up study collecting biological samples

  This study tests how often cancer patients who have had a VTE will experience more clots over time and gathers blood and urine samples to explore why it happens.

  Recruiting University Hospital, Brest · Brest · NCT06393764

• Using apixaban to prevent strokes in patients with severe kidney disease and atrial fibrillation

  This study is testing if the blood thinner apixaban can help prevent strokes in people with severe kidney disease and atrial fibrillation.

  Recruiting at 29 sites Phase 3 Region Stockholm · Helsinki and 33 other locations · NCT05679024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.